CE / CME
Gain expert perspectives on the most clinically relevant data on breast, lung, gastrointestinal, genitourinary, and skin cancers presented at the 2023 ESMO Congress.
Physician Assistants/Physician Associates: 1.50 AAPA Category 1 CME credits
Nurses: 1.50 Nursing contact hours
Physicians: maximum of 1.50 AMA PRA Category 1 Credits™
Pharmacists: 1.50 contact hours (0.15 CEUs)
Released: December 22, 2023
Expiration: December 21, 2024
Share
Natasha Leighl, MD, MMSc, FRCPC, FASCO
Lung Medical Oncology Site Lead
OSI Pharmaceuticals Foundation Chair
Princess Margaret Cancer Centre
Professor of Medicine
University of Toronto
Toronto, Canada
Evan J. Lipson, MD
Associate Professor of Oncology
Melanoma and Cancer Immunology Programs
Bloomberg-Kimmel Institute for Cancer Immunotherapy
Johns Hopkins University School of Medicine
Sidney Kimmel Comprehensive Cancer Center
Baltimore, Maryland
John Marshall, MD
Medstar Hematology/Oncology
Director, Ruesch Center for Cure of GI Cancers
Lombardi Comprehensive Cancer Center Georgetown University
Washington, DC
Joyce O'Shaughnessy, MD
Celebrating Women Chair in Breast Cancer Research
Baylor University Medical Center
Chair, Breast Disease Committee
Sarah Cannon Research Institute
Texas Oncology
Dallas, Texas
Daniel P. Petrylak, MD
Professor of Medicine (Medical Oncology) and of Urology
Director, Prostate and GU Medical Oncology
Yale Cancer Center
New Haven, Connecticut
Provided by Clinical Care Options, LLC
Supported by educational grants from AstraZeneca, Bristol Myers Squibb, Daiichi Sankyo, Inc., Exelixis, Inc., Gilead Sciences, Inc., Lilly and Regeneron Pharmaceuticals, Inc.
AstraZeneca
Bristol Myers Squibb
Daiichi Sankyo, Inc.
Exelixis, Inc.
Gilead Sciences, Inc.
Lilly
Regeneron Pharmaceuticals, Inc
This program is intended for physicians, physician associates, nurses, pharmacists, and other healthcare professionals caring for cancer patients.
The goal of this program is to improve the knowledge and competence of learners in effort to optimize treatment for patients with Multitumor
Upon completion of this activity, participants should be able to:
Integrate recently presented data, as appropriate and guided by expert recommendations, to optimize care for patients with cancer
Distinguish subpopulations of cancer patients most likely to benefit from specific treatment based on prognostic or predictive markers
Interpret new data on novel agents and therapeutic strategies for patients with cancer to aid optimal integration into practice
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:
Primary Author
Natasha Leighl, MD, MMSc, FRCPC, FASCO
Lung Medical Oncology Site Lead
OSI Pharmaceuticals Foundation Chair
Princess Margaret Cancer Centre
Professor of Medicine
University of Toronto
Toronto, Canada
Natasha Leighl, MD, FRCPC, FASCO: researcher (paid to institution): Amgen, AstraZeneca, Guardant Health, Lilly; consultant/advisor/speaker: AstraZeneca, Beigene, Bristol-Myers Squibb, Janssen, Merck, Novartis, Takeda.
Evan J. Lipson, MD
Associate Professor of Oncology
Melanoma and Cancer Immunology Programs
Bloomberg-Kimmel Institute for Cancer Immunotherapy
Johns Hopkins University School of Medicine
Sidney Kimmel Comprehensive Cancer Center
Baltimore, Maryland
Evan J. Lipson, MD: consultant/advisor/speaker: Bristol-Myers Squibb, CareDX, Eisai, Genentech, HUYA Bioscience International, Immunocore, Instil Bio, Merck, Natera, Nektar, Novartis, Oncosec, Pfizer, Rain Therapeutics, Regeneron, Replimune, Sanofi-Aventiz; researcher (paid to institution): Bristol-Myers Squibb, Haystack, Merck, Regeneron, Sanofi.
John Marshall, MD
Medstar Hematology/Oncology
Director, Ruesch Center for Cure of GI Cancers
Lombardi Comprehensive Cancer Center Georgetown University
Washington, DC
John Marshall, MD: consultant/advisor/speaker: Arcus, AstraZeneca, Bayer, Caris, Merck, Pfizer, Seagen, Taiho, Takeda.
Joyce O'Shaughnessy, MD
Celebrating Women Chair in Breast Cancer Research
Baylor University Medical Center
Chair, Breast Disease Committee
Sarah Cannon Research Institute
Texas Oncology
Dallas, Texas
Joyce O'Shaughnessy, MD: consultant/advisor/speaker: AbbVie Inc., Agendia, Aptitude Health, AstraZeneca, Bayer, Bristol Myers Squibb, Caris, Carrick Therapeutics, Celgene Corporation, Daiichi Sankyo, Eisai, Exact Sciences, Fishawack Health, G1 Therapeutics, GlaxoSmithKline, Genentech, Gilead Sciences, Immunomedics, Incyte Corporation, Lilly, Loxo Oncology, Merck, Novartis, Ontada, Pfizer, Pharmacyclics, Pierre Fabre Pharmaceuticals, Puma Biotechnology, Prime Oncology, Roche, Samsung Bioepis, Sanofi, Seagen, Stemline Therapeutics, Theralink, Synthon, Veru.
Daniel P. Petrylak, MD
Professor of Medicine (Medical Oncology) and of Urology
Director, Prostate and GU Medical Oncology
Yale Cancer Center
New Haven, Connecticut
Daniel P. Petrylak, MD: consultant/advisor/speaker: Ada Cap (Advanced Accelerator Applications) Amgen, Astellas, AstraZeneca, Bayer, Bicycle Therapeutics, Boehringer Ingelheim, Bristol-Myers Squibb, Clovis Oncology, Exelixis, Gilead Sciences, Incyte, Infinity Pharmaceuticals, Ipsen, Janssen, Lilly, Mirati, Monopteros, Pfizer, Pharmacyclics, Regeneron, Roche, Seattle Genetics, Urogen; researcher: Ada Cap (Advanced Accelerator Applications), Agensys Inc, Arvinas, Astellas, AstraZeneca, Bayer, BioXcel Therapeutics, Bristol-Myers Squibb, Clovis Oncology, Eisai, Endocyte, Genentech, Gilead Sciences, Innocrin, Lilly, MedImmune, Medivation, Merck, Mirati, Novartis, Pfizer, Progenics, Replimune, Roche, Sanofi Aventis, Seattle Genetics.
The planners and content peer reviewers from Clinical Care Options, LLC do not have any relevant financial relationships to disclose, except Kristi K. Orbaugh, MSN, NP, AOCNP, as noted below.
Kristi K. Orbaugh, MSN, NP, AOCNP: consultant/advisor/speaker: AstraZeneca, Bristol Myers Squibb, CTI, DSI, Gilead, Lilly, MorphoSys, Pfizer.
Participation in this self-study activity should be completed in approximately 1.5 hours. To successfully complete this activity and receive credit, learners must follow these steps during the period from December 22, 2023, through December 21, 2024:
You must receive a test score of at least 65 and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the confirmation page. Records of all CME/CE activities completed can be found on the "My Certificates" page. There are no costs/fees for this activity.
This program has been made available online.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Joint Accreditation StatementIn support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Continuing Medical Education
CCO designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nursing Continuing Professional Development
The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 1.5 contact hours.
Continuing Pharmacy Education
CCO designates this continuing education activity for 1.5 contact hours (0.15 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number - JA4008176-0000-23-327-H01-P
Type of Activity: Application
Upon successfully completing the post-test with a score of 65 or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.
Physician Associate Continuing Medical EducationClinical Care Option, LLC has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.5 AAPA Category 1 CME credits. Approval is valid until December 21, 2024. PAs should only claim credit commensurate with the extent of their participation.